Literature DB >> 19481078

B30.2/SPRY domain in tripartite motif-containing 22 is essential for the formation of distinct nuclear bodies.

Gayathri Sivaramakrishnan1, Yang Sun, Rajamuthiah Rajmohan, Valerie C L Lin.   

Abstract

Tripartite motif-containing 22 (TRIM22) is an important antiviral protein that forms distinct nuclear bodies (NB) in many cell types. This study aims to identify functional domains/residues for TRIM22's nuclear localization and NB formation. Deletion of the really-interesting-new-gene (RING) domain, which is essential for its antiviral property, abolished TRIM22 NB formation. However, mutation of two critical residues Cys15 and Cys18 to alanine in the RING domain, did not affect NB formation notably. Although the deletion of the putative bipartite nuclear localization signal (NLS) abolished TRIM22 localization and NB formation, the B30.2/SplA and ryanodine receptor (SPRY) domain, and residues 491-494 specifically are also essential for nuclear localization and NB formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481078     DOI: 10.1016/j.febslet.2009.05.036

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements.

Authors:  Anna Kajaste-Rudnitski; Sara S Marelli; Cinzia Pultrone; Thomas Pertel; Pradeep D Uchil; Nadir Mechti; Walther Mothes; Guido Poli; Jeremy Luban; Elisa Vicenzi
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

2.  TRIM22 inhibits the TRAF6-stimulated NF-κB pathway by targeting TAB2 for degradation.

Authors:  Hui Qiu; Fang Huang; Han Xiao; Binlian Sun; Rongge Yang
Journal:  Virol Sin       Date:  2013-06-26       Impact factor: 4.327

3.  TRIM22: A Diverse and Dynamic Antiviral Protein.

Authors:  Clayton J Hattlmann; Jenna N Kelly; Stephen D Barr
Journal:  Mol Biol Int       Date:  2012-05-08

4.  In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.

Authors:  Jenna N Kelly; Stephen D Barr
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

5.  TRIM22-Mediated Apoptosis is Associated with Bak Oligomerization in Monocytes.

Authors:  Chi Chen; DongYan Zhao; Shu Fang; QiXing Chen; BaoLi Cheng; XiangMing Fang; Qiang Shu
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

Review 6.  Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses.

Authors:  Greta Forlani; Roberto S Accolla
Journal:  Front Immunol       Date:  2017-10-18       Impact factor: 7.561

7.  Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1.

Authors:  Greta Forlani; Giovanna Tosi; Filippo Turrini; Guido Poli; Elisa Vicenzi; Roberto S Accolla
Journal:  Front Immunol       Date:  2017-05-15       Impact factor: 7.561

8.  Nuclear localization signal in TRIM22 is essential for inhibition of type 2 porcine reproductive and respiratory syndrome virus replication in MARC-145 cells.

Authors:  Huiyuan Jing; Ran Tao; Nan Dong; Sufang Cao; Yanting Sun; Wenting Ke; Yang Li; Jinhe Wang; Yan Zhang; Hui Huang; Wang Dong
Journal:  Virus Genes       Date:  2019-08-02       Impact factor: 2.332

9.  Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes.

Authors:  Tejaswini S Reddi; Philipp E Merkl; So-Yon Lim; Norman L Letvin; David M Knipe
Journal:  PLoS Pathog       Date:  2021-02-01       Impact factor: 6.823

10.  TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα.

Authors:  Jianxiong Ji; Kaikai Ding; Tao Luo; Xin Zhang; Anjing Chen; Di Zhang; Gang Li; Frits Thorsen; Bin Huang; Xingang Li; Jian Wang
Journal:  Cell Death Differ       Date:  2020-08-19       Impact factor: 15.828

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.